Pay in 4 interest-free payments of $5.51 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
A similar pattern was observed in the SURMOUNT-4 trial for tirzepatide: after participants lost an average of 20.9% of their body weight during a 36-week lead-in phase, those who stopped treatment regained about 14%, while those who continued taking tirzepatide lost an additional 5.5% over the next year
,
Some of these drugs are being prescribed for off label use which includes 1) drugs approved for diabetes used for weight loss (for example, Ozempic) or 2) drugs approved for weight loss in obese patients or patients with weight-related medical conditions prescribed to patients who do not meet these criteria
Contraindications: Not advised for individuals with prostate cancer or other hormone-dependent tumors
Doran AC, Yurdagul A, Tabas I
US$ 24.87
US$ 26.66
US$ 28.23
.webp?width=900&height=1201&name=Semaglutide%20Image%202_900x1200%20(without%20phone).webp)
